Michelle Ho, Ph.D.

Michelle Ho, Ph.D. joined 5AM Ventures in 2018 as an Analyst and was promoted to Senior Associate in 2022. Dr. Ho serves as an Observer of the Boards of Artiva Biotherapeutics, Cleave Therapeutics, Ensoma, Purigen, Radionetics Oncology and RareCyte. Through 5AM’s 4:59 Initiative, she helped to build and launch Ensoma, serving as acting Head of Corporate Strategy. Prior to 5AM, Dr. Ho was an Entrepreneurship Fellow at Fannin Innovation Studio, where she led R&D and BD for two life science startups in Houston, TX. Previously, Dr. Ho was a T32 Postdoctoral Fellow in the Department of Gynecologic Oncology at MD Anderson Cancer Center and the Department of Bioengineering at Rice University developing targeted AAV vectors for ovarian cancer treatment. She earned her Ph.D. in Bioengineering from Rice University developing next-generation AAV-based gene therapy vectors in the Suh Lab. She received her B.S. in Bioengineering from the University of California – Berkeley, where she was a Regents’ and Chancellor’s scholar. Dr. Ho is based in the San Francisco, CA office.